M&A activity is picking up among pharmaceutical firms with large cash balances. Pfizer and Amgen have each closed a multi-billion…
McAlinden Research PartnersAugust 9, 2022
The number of cyberattacks are on the rise, but the average cost of each attack is increasing even faster. Billions of…
McAlinden Research PartnersJuly 22, 2022
US banks' second quarter results helped to map out an uncertain future for the financial sector. Trading revenues rose but…
McAlinden Research PartnersJuly 19, 2022
Psychedelic medicine, focused on alternative mental health therapies that utilize drugs like LSD, MDMA and psilocybin, is becoming increasingly popular…
McAlinden Research PartnersJuly 18, 2022
Last year marked one of the least active years for biopharma merger and acquisition (M&A) activity in a decade. The first…
McAlinden Research PartnersJuly 14, 2022
A decade after its discovery, an authorization of CRISPR drugs to be marketed in the US may only be a…
McAlinden Research PartnersJuly 11, 2022
The Federal Reserve will publish results from their annual stress tests of major US financial institutions today after the close. Based on those,…
McAlinden Research PartnersJune 23, 2022
Numerous Bitcoin ETFs have been approved by the SEC over the last year, but a spot fund, widely-regarded as the…
McAlinden Research PartnersJune 22, 2022
Emerging Markets Face a Fragmented Future as Buoyant Dollar and Chinese Loans Fuel Debt Crisis Fears
Emerging Markets continue to languish under a strong USD and fading growth prospects. Each of those factors are intensifying the large…
McAlinden Research PartnersJune 21, 2022
